Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.

A Tempero, Margaret; Pelzer, Uwe; M O'Reilly, Eileen; Winter, Jordan; Oh, Do-Youn; Li, Chung-Pin; Tortora, Giampaolo; Chang, Heung-Moon; D Lopez, Charles; Bekaii-Saab, Tanios; H Ko, Andrew; Santoro, Armando; Oh Park, Joon; S Noel, Marcus; Luca Frassineti, Giovanni; Shan, Yan-Shen; Dean, Andrew; Riess, Hanno; Van Cutsem, Eric; Berlin, Jordan; Philip, Philip; Moore, Malcolm; Goldstein, David; Tabernero, Josep; Li, Mingyu; Ferrara, Stefano; Le Bruchec, Yvan; Zhang, George; Lu, Brian; V Biankin, Andrew; Reni, Michele; Investigators, APACT

doi:10.1200/jco.22.01134

Public

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Apr 10, 2023

NobleIDark:/48914/w1/20260526/FE873D73Record on NobleID

Authors:

Margaret A Tempero

,

Uwe Pelzer

,

Eileen M O'Reilly

Abstract

PURPOSE: This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). METHODS: We assigned 866 treatment-naive patients with pancreatic...

Discussions